Design of retroviral vectors and helper cells for gene therapy

Pharmacological Reviews

Volumn 52, Issue 4, 2000, Pages 493-511

  Hu, Wei Shau ^a,b   Pathak, Vinay K ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

AMINO ACID SEQUENCE; AVIAN LEUKOSIS ONCOVIRUS; GENE AMPLIFICATION; GENE STRUCTURE; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HELPER CELL; LENTIVIRINAE; MURINE LEUKEMIA VIRUS; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; REVIEW; ROUS SARCOMA ONCOVIRUS; SPUMA VIRUS; VIRUS REPLICATION;

ANIMALS; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; HUMANS; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; VIRUS REPLICATION;

EID: 0033639189     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (165)

1. Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions
2. R-region cDNA inserts in retroviral vectors are compatible with virus replication and high-level protein synthesis from the insert
3. End-of-the-year potpourri - 1996
4. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region
5. RNA packaging
6. An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors
7. An internal ribosomal entry signal in the rat VL30 region of the Harvey murine sarcoma virus leader and its use in dicistronic retroviral vectors
8. Steps toward gene therapy: 1. The initial trials
9. Steps toward gene therapy: 2. Cancer and AIDS
10. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
11. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
12. A new defective retroviral vector system based on the Bryan strain of Rous sarcoma virus
13. Animal virus pseudotypes
14. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
15. Relative rates of retroviral reverse transcriptase template switching during RNA- and DNA-dependent DNA synthesis
16. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent
17. Gene therapy for head and neck cancer
18. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
19. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
20. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: A new system for anti-human immunodeficiency virus gene therapy
21. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
22. The nucleocapsid domain is responsible for the ability of spleen necrosis virus (SNV) Gag polyprotein to package both SNV and murine leukemia virus RNA
23. Nonreciprocal pseudotyping: Murine leukemia virus proteins cannot efficiently package spleen necrosis virus-based vector RNA
24. Modification of retroviral tropism by display of IGF-I
25. Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site
26. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer
27. Controlling mammalian gene expression with small molecules
28. Noninfectious gene transfer and expression systems for cancer gene therapy
29. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system
30. Anti-HIV effects of HIV vectors
31. Packaging cells for avian leukosis virus-based vectors with various host ranges
32. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges
33. The sequence context of the initiation codon in the encephalomyocarditis virus leader modulates efficiency of internal translation initiation
34. Psi-vectors: Murine leukemia virus-based self-inactivating and self-activating retroviral vectors
35. Development of murine leukemia virus-based self-activating vectors that efficiently delete the selectable drug resistance gene during reverse transcription
36. Effect of distance between homologous sequences and 3' homology on the frequency of retroviral reverse transcriptase template switching
37. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
38. Reticuloendotheliosis viruses and derived vectors
39. High mutation rate of a spleen necrosis virus-based retrovirus vector
40. A promoterless retroviral vector indicates that there are sequences in U3 required for 3' RNA processing
41. New retrovirus helper cells with almost no nucleotide sequence homology to retrovirus vectors
42. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
43. Gene transfer to hematopoietic stem cells: Implications for gene therapy of human disease
44. Lack of competition results in efficient packaging of heterologous murine retroviral RNAs and reticuloendotheliosis virus encapsidation-minus RNAs by the reticuloendotheliosis virus helper cell line
45. Transcription from a spleen necrosis virus 5' long terminal repeat is suppressed in mouse cells
46. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism
47. High-frequency deletion in recovered retrovirus vectors containing exogenous DNA with promoters
48. Comparison of promoter suppression in avian and murine retrovirus vectors
49. Quantitative analysis of gene suppression in integrated retrovirus vectors
50. Sequences in pol are required for transfer of human foamy virus-based vectors
51. Cre/loxP-mediated excision of a neomycin resistance expression unit from an integrated retroviral vector increases long terminal repeat-driven transcription in human hematopoietic cells
52. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers
53. kat: A high-efficiency retroviral transduction system for primary human T lymphocytes
54. Adeno-associated virus vectors for gene therapy
55. HIV-1: Fifteen proteins and an RNA
56. A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects
57. Advanced transgenic and gene-targeting approaches
58. Development and application of herpes simplex virus vectors for human gene therapy
59. Helper-independent retrovirus vectors with Rous-associated virus type O long terminal repeats
60. Retroviral vector targeting for gene therapy
61. Ligand-directed retroviral targeting of human breast cancer cells
62. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector
63. Inducible control of gene expression: Prospects for gene therapy
64. RNA packaging signal of human immunodeficiency virus type 1
65. Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors
66. Inducible and constitutive transcription factors in the mammalian nervous system: Control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins
67. The nature of the interaction of the P1 recombinase Cre with the recombining site loxP
68. Genetic consequences of packaging two RNA genomes in one retroviral particle: Pseudodiploidy and high rate of genetic recombination
69. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors
70. The genetic modification of T cells for cancer therapy: An overview of laboratory and clinical trials
71. Cap-independent translation of picornavirus RNAs: Structure and function of the internal ribosomal entry site
72. Cap-independent translation of encephalomyocarditis virus RNA: Structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein
73. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
74. In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies
75. E-vectors: Development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy
76. Strong immunogenic potential of a B7 retroviral expression vector: Generation of HLA-B7-restricted CTL response against selectable marker genes
77. Cell targeting by morine retroviral vectors
78. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
79. Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: A possible role for the p2 domain of Gag in RNA encapsidation
80. cis-Acting sequences involved in human immunodeficiency virus type 1 RNA packaging
81. Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody
82. Spleen necrosis virus, an avian retrovirus, can infect primate cells
83. Ping-pong amplification of a retroviral vector achieves high-level gene expression: Human growth hormone production
84. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells
85. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions
86. Human immunodeficiency virus infection of cells arrested in the cell cycle
87. Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors
88. Foamy viruses are unconventional retroviruses
89. Retroviral RNA packaging: Sequence requirements and implications
90. Characterization of an internal ribosomal entry segment within the 5' leader of avian reticuloendotheliosis virus type A RNA and development of novel MLV-REV-based retroviral vectors
91. Interleukin 12: Cellular and molecular immunology of an important regulatory cytokine. Introduction
92. Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response
93. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus
94. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene
95. The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate
96. Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments
97. Human genome: Rival genome sequencers celebrate a milestone together
98. Improved retroviral packaging lines derived from spleen necrosis virus
99. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures
100. Position dependence of functional hairpins important for human immunodeficiency virus type 1 RNA encapsidation in vivo
101. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation
102. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production
103. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus
104. Human foamy virus reverse transcription that occurs late in the viral replication cycle
105. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins
106. Application of exogenously regulatable promoter systems to transgenic models for the study of aging
107. Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors
108. A molecular genetic intervention for AIDS - Effects of a transdominant negative form of Rev
109. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
110. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses
111. Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm
112. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
113. Improved self-inactivating retroviral vectors derived from spleen necrosis virus
114. Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion
115. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes
116. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: Deletions and deletions with insertions
117. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA
118. Human genome: Finally, the book of life and instructions for navigating it
119. Replication-competent retrovirus vectors for the transfer and expression of gene cassettes in avian cells
120. Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors
121. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
122. Gene transfer: A review of methods and applications
123. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer
124. Retroviral RNA packaging: A review
125. Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5' leader region
126. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles
127. Viral vectors for gene therapy
128. Recent advances in inducible gene expression systems
129. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
130. Self-deleting retrovirus vectors for gene therapy
131. Inducible gene expression in mammalian cells and transgenic mice
132. Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors
133. Viral vectors in gene therapy
134. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
135. A transient three-plasmid expression system for the production of high titer retroviral vectors
136. Development of avian sarcoma and leukosis virus-based vector-packaging cell lines
137. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
138. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication
139. In vitro analysis of a primary, major histocompatibility complex (MHC)-restricted, cytotoxic T-lymphocyte response to avian leukosis virus (ALV), using target cells expressing MHC class I cDNA inserted into a recombinant ALV vector
140. Puffs and gene regulation - Molecular insights into the Drosophila ecdysone regulatory hierarchy
141. Helper-free foamy virus vectors
142. Insertion of the human cytomegalovirus enhancer into a myeloproliferative sarcoma virus long terminal repeat creates a high-expression retroviral vector
143. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis
144. Retroviral vectors. From laboratory tools to molecular medicine
145. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting
146. Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene
147. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors
148. Lentivirus vectors using human and simian immunodeficiency virus elements
149. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA
150. cis-Acting sequences required for simian foamy virus type 1 vectors
151. Developing particle-mediated gene-transfer technology for research into gene therapy of cancer
152. Generation of retroviral vector for clinical studies using transient transfection
153. Generation of high-titer pseudotyped retroviral vectors with very broad host range
154. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes
155. Inducible human immunodeficiency virus type 1 packaging cell lines
156. Human foamy virus replication: A pathway distinct from that of retroviruses and hepadnaviruses
157. Evidence that the human foamy virus genome is DNA
158. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells
159. Viral pseudotypes and phenotypic mixing